Predictive biomarkers for checkpoint inhibitor-based immunotherapy

The Lancet Oncology

Volumn 17, Issue 12, 2016, Pages e542-e551

  Gibney, Geoffrey T ^a   Weiner, Louis M ^a   Atkins, Michael B ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; CHECKPOINT INHIBITOR; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; PROTEIN ANTIBODY; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CD274 PROTEIN, HUMAN;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; GENE; HUMAN; IMMUNE GENE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MONOTHERAPY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SOMATIC MUTATION; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES;

ANTIGENS, CD274; BIOMARKERS; CELL CYCLE CHECKPOINTS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 85003475383     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30406-5     Document Type: Review

References (67)

1. 1 Hanahan, D, Weinberg, RA, Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
2. 2 Chen, DS, Mellman, I, Oncology meets immunology: the cancer-immunity cycle. Immunity 39 (2013), 1–10.
3. 3 Gajewski, TF, Schreiber, H, Fu, YX, Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14 (2013), 1014–1022.
4. 4 Spranger, S, Spaapen, RM, Zha, Y, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med, 5, 2013, 200ra116.
5. 5 Atkins, MB, Lotze, MT, Dutcher, JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17 (1999), 2105–2116.
6. 6 Rosenberg, SA, Yang, JC, Sherry, RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17 (2011), 4550–4557.
7. 7 Hodi, FS, O'Day, SJ, McDermott, DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
8. 8 Robert, C, Thomas, L, Bondarenko, I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364 (2011), 2517–2526.
9. 9 Schadendorf, D, Hodi, FS, Robert, C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33 (2015), 1889–1894.
10. 10 Borghaei, H, Paz-Ares, L, Horn, L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
11. 11 Brahmer, J, Reckamp, KL, Baas, P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373 (2015), 123–135.
12. 12 Garon, EB, Rizvi, NA, Hui, R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372 (2015), 2018–2028.
13. 13 Larkin, J, Chiarion-Sileni, V, Gonzalez, R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 23–34.
14. 14 Robert, C, Long, GV, Brady, B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372 (2015), 320–330.
15. 15 Motzer, RJ, Escudier, B, McDermott, DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1803–1813.
16. 16 Homet Moreno, B, Ribas, A, Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer 112 (2015), 1421–1427.
17. 17 Hammers, HJ, Plimack, ER, Infante, JR, et al. Expanded cohort results from CheckMate 016: a phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). Proc Am Soc Clin Oncol, 33, 2015 (abstr 4516).
18. 18 Hellmann, MD, Gettinger, SN, Goldman, JW, et al. CheckMate 012: safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. Proc Am Soc Clin Oncol, 2016, 34 (abstr 3001).
19. 19 Topalian, SL, Hodi, FS, Brahmer, JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (2012), 2443–2454.
20. 20 Mahoney, KM, Atkins, MB, Prognostic and predictive markers for the new immunotherapies. Oncology, 28(suppl 3), 2014 39–48.
21. 21 Chen, J, Jiang, CC, Jin, L, Zhang, XD, Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol 27 (2016), 409–416.
22. 22 Ansell, SM, Lesokhin, AM, Borrello, I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372 (2015), 311–319.
23. 23 Mansfield, AS, Murphy, SJ, Peikert, T, et al. Heterogeneity of programmed cell death ligand 1 expression in multifocal lung cancer. Clin Cancer Res 22 (2016), 2177–2182.
24. 24 Patel, SP, Kurzrock, R, PD-L1 Expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14 (2015), 847–856.
25. 25 Wolchock JD, Chiarion-Sileni V, Gonzalez R, et al. Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). 2016 ASCO Annual Meeting; Chicago, IL; June 3–7, 2016. Abstr 9505.
26. 26 Hamid, O, Schmidt, H, Nissan, A, et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med, 9, 2011, 204.
27. 27 Tumeh, PC, Harview, CL, Yearley, JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515 (2014), 568–571.
28. 28 Chen, PL, Roh, W, Reuben, A, et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov 6 (2016), 827–837.
29. 29 Le, DT, Uram, JN, Wang, H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372 (2015), 2509–2520.
30. 30 Le, DT, Uram, JN, Wang, H, et al. Programmed death-1 blockade in mismatch repair deficient colorectal cancer. Proc Am Soc Clin Oncol, 2016, 34 (abstr 103).
31. 31 Snyder, A, Makarov, V, Merghoub, T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371 (2014), 2189–2199.
32. 32 Van Allen, EM, Miao, D, Schilling, B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350 (2015), 207–211.
33. 33 Rizvi, NA, Hellmann, MD, Snyder, A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
34. 34 Johnson, DB, Frampton, GM, Rioth, MJ, et al. Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-PD-1/PD-L1. Proc Am Soc Clin Oncol, 2016, 34 (abstr 105).
35. 35 Rosenberg, JE, Hoffman-Censits, J, Powles, T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387 (2016), 1909–1920.
36. 36 Hugo, W, Zaretsky, JM, Sun, L, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165 (2016), 35–44.
37. 37 McGranahan, N, Furness, AJ, Rosenthal, R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351 (2016), 1463–1469.
38. 38 Ji, RR, Chasalow, SD, Wang, L, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 61 (2012), 1019–1031.
39. 39 Ribas, A, Robert, C, Hodi, FS, et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. Proc Am Soc Clin Oncol, 33, 2015 (abstr 3001).
40. 40 Huh, JW, Lee, JH, Kim, HR, Prognostic significance of tumor-infiltrating lymphocytes for patients with colorectal cancer. Arch Surg 147 (2012), 366–372.
41. 41 Thomas, NE, Busam, KJ, From, L, et al. Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. J Clin Oncol 31 (2013), 4252–4259.
42. 42 Zeng, DQ, Yu, YF, Ou, QY, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer. Oncotarget 7 (2016), 13765–13781.
43. 43 Messina, JL, Fenstermacher, DA, Eschrich, S, et al. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?. Sci Rep, 2, 2012, 765.
44. 44 Tokito, T, Azuma, K, Kawahara, A, et al. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy. Eur J Cancer 55 (2016), 7–14.
45. 45 Castle, JC, Kreiter, S, Diekmann, J, et al. Exploiting the mutanome for tumor vaccination. Cancer Res 72 (2012), 1081–1091.
46. 46 Matsushita, H, Vesely, MD, Koboldt, DC, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482 (2012), 400–404.
47. 47 Rooney, MS, Shukla, SA, Wu, CJ, Getz, G, Hacohen, N, Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160 (2015), 48–61.
48. 48 Schumacher, TN, Schreiber, RD, Neoantigens in cancer immunotherapy. Science 348 (2015), 69–74.
49. 49 Ferrucci, PF, Ascierto, PA, Pigozzo, J, et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol 27 (2016), 732–738.
50. 50 Martens, A, Wistuba-Hamprecht, K, Geukes-Foppen, M, et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res 22 (2016), 2908–2918.
51. 51 Delyon, J, Mateus, C, Lefeuvre, D, et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol 24 (2013), 1697–1703.
52. 52 Ku, GY, Yuan, J, Page, DB, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 116 (2010), 1767–1775.
53. 53 Simeone, E, Gentilcore, G, Giannarelli, D, et al. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother 63 (2014), 675–683.
54. 54 Weide, B, Martens, A, Hassel, JC, et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-16-0127 published online May 16.
55. 55 Weber, JS, Kudchadkar, RR, Yu, B, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol 31 (2013), 4311–4318.
56. 56 Gibney, GT, Kudchadkar, RR, DeConti, RC, et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res 21 (2015), 712–720.
57. 57 Postow, MA, Manuel, M, Wong, P, et al. Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma. J Immunother Cancer, 3, 2015, 23.
58. 58 Johnson, DB, Estrada, MV, Salgado, R, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun, 7, 2016, 10582.
59. 59 Yuan, J, Hegde, PS, Clynes, R, et al. Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother Cancer, 4, 2016, 3.
60. 60 Feng, Z, Puri, S, Moudgil, T, et al. Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma. J Immunother Cancer, 3, 2015, 47.
61. 61 Kluger, HM, Zito, CR, Barr, ML, et al. Characterization of PD-L1 expression and associated T-cell infiltrates in metastatic melanoma samples from variable anatomic sites. Clin Cancer Res 21 (2015), 3052–3060.
62. 62 Taube, JM, Klein, A, Brahmer, JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20 (2014), 5064–5074.
63. 63 Matsushita, H, Sato, Y, Karasaki, T, et al. Neoantigen load, antigen presentation machinery, and immune signatures determine prognosis in clear cell renal cell carcinoma. Cancer Immunol Res 4 (2016), 463–471.
64. 64 Taube, JM, Young, GD, McMiller, TL, et al. Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockade. Clin Cancer Res 21 (2015), 3969–3976.
65. 65 Higgs, BW, Morehouse, C, Streicher, K, et al. Relationship of baseline tumoral IFNγ mRNA and PD-L1 protein expression to overall survival in durvalumab-treated NSCLC patients. Proc Am Soc Clin Oncol, 2016, 34 (abstr 3036).
66. 66 Higgs BW, Robbins PB, Blake-Haskins JA et al. High tumoral IFNγ mRNA, PD-L1 protein, and combined IFNγ mRNA/PD-L1 protein expression associates with response to durvalumab (anti-PD-L1) monotherapy in NSCLC patients. European Cancer Congress 2015; Vienna; Sept 25–29. Abstr 15LBA.
67. 67 Spranger, S, Bao, R, Gajewski, TF, Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 523 (2015), 231–235.